TABLE 2.
Hemolysin production by human isolates of M. avium in relation to clinical specimen, sequevar, and patient's HIV status
| Clinical specimen and sequevar | No. of isolates from HIV+ patients/total no. of isolates | Results for hemolysin production
|
||||
|---|---|---|---|---|---|---|
| No. of strains with the indicated level of hemolysisa
|
A520+/A520−b | |||||
| None | S | M | W | |||
| Blood | ||||||
| Mav-A | 2/2 | 2 | 2.48 ± 0.66 | |||
| Mav-B | 14/14 | 1 | 11 | 1 | 1 | 2.51 ± 0.69 |
| Mav-C | 1/1 | 1 | 1.64 | |||
| Pulmonary | ||||||
| Mav-A | 1/5 | 5 | 2.77 ± 0.46 | |||
| Mav-B | 0/1 | 1 | 2.27 | |||
| Otherc | ||||||
| Mav-A | 3/4 | 3 | 1 | 2.28 ± 0.27 | ||
a
S, strong; M, moderate; W, weak. None, not hemolytic.
b
Means ± SD of the ratios between the absorbance values obtained in the presence (A520+) and in the absence (A520−) of tested bacteria. Only hemolytic strains were considered.
c
Specimens other than blood and pulmonary samples included urine (two specimens), cerebrospinal fluid, and stool samples.